Filters
Price
Category
Peptides
Administration
Dosage
Research Focus
Brand
Rating
Status
Best Sellers
-
Ghk-Cu - Cream
£5.99 – £10.99Price range: £5.99 through £10.99
- Ipamorelin £36.99 – £45.99Price range: £36.99 through £45.99
-
GHK-CU (Vial)
£19.99 – £23.99Price range: £19.99 through £23.99mg
-
SLU-PP-332
£79.99
-
KissPeptin-10
£42.99 – £54.99Price range: £42.99 through £54.99
Showing all 3 results
Showing all 3 results
CJC-1295 (No DAC)
£32.99 – £48.99Price range: £32.99 through £48.99CJC-1295 (No DAC)
Hormonal — GHRH Analogue CJC-1295 is a synthetic GHRH analogue. The no-DAC variant produces short, pulsatile GH release closely mimicking natural physiology and is commonly combined with Ipamorelin for synergistic effect across the GH axis. Target: GHRH receptor Variant: No-DAC (short-acting) Half-Life: ~30 min (no DAC)
CJC-1295 (With DAC)
£36.99 – £45.99Price range: £36.99 through £45.99CJC-1295 (With DAC)
Hormonal — GHRH Analogue CJC-1295 is a synthetic GHRH analogue. The DAC (Drug Affinity Complex) variant binds circulating albumin, extending its half-life to several days for sustained growth-hormone elevation rather than the short pulsatile release of the no-DAC form. Target: GHRH receptor Variant: With DAC (long-acting) Half-Life: ~6–8 days
Tesamorelin
£22.99 – £90.99Price range: £22.99 through £90.99Tesamorelin
Hormonal — GHRH Analogue Tesamorelin
An FDA-approved synthetic GHRH analogue (Egrifta®) for the reduction of excess visceral adipose tissue in HIV-associated lipodystrophy.
It is unique among GH-axis peptides in having genuine regulatory approval, and its clinical data provides high-quality evidence for its mechanism and effects on body composition.
- Approval: FDA 2010 (Egrifta®)
- Indication: HIV lipodystrophy — visceral fat
- Half-Life: ~26 minutes










